Cell body infusions of brain-derived neurotrophic factor increase forebrain dopamine release and serotonin metabolism determined with in vivo microdialysis.
Altar
C A
CA
Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
Fritsche
M
M
Lindsay
R M
RM
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D008636:Mesencephalon / Q000187:drug effects / Q000502:physiology*; D017551:Microdialysis / Q000379:methods; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000494:pharmacology; D020933:Neurotrophin 3; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism*; D011903:Raphe Nuclei / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism*; D010133:p-Chloroamphetamine / Q000008:administration & dosage / Q000494:pharmacology
D019208:Brain-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D020933:Neurotrophin 3; D011994:Recombinant Proteins; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D010133:p-Chloroamphetamine; D003913:Dextroamphetamine; D004298:Dopamine; D006719:Homovanillic Acid